Global Choroidal Neovascularization Market 2016-2020

Table of Content

PART 01: Executive summary

• Highlights

PART 02: Scope of  the report

• Market overview
• Top-vendor offerings

PART 03: Market research methodology

• Research methodology
• Economic indicators

PART 04: Introduction

• Key market highlights
• Key buying criteria

PART 05: Disease overview

• Introduction
• Pathophysiology
• Symptoms
• Management
• Epidemiology

PART 06: Product portfolio of approved therapies

PART 07: Pipeline analysis

• OHR-102
• RTH258
• Fovista
• RG7716
• PF-04523655
• NT-503
• LFG316
• REGN2176-3
• Zimura
• LHA510
• DE-120

PART 08: Market landscape

• Market overview
• Market size and forecast
• Five forces analysis

PART 09: Market segmentation by ROA

• IV
• Intravitreal

PART 10: Geographical segmentation

• Global choroidal neovascularization market by geographical segmentation 2015-2020
• Choroidal neovascularization market in Americas
• Choroidal neovascularization market in EMEA
• Choroidal neovascularization market in APAC

PART 11: Market drivers

• Growing older population
• Increased prevalence of chronic diseases
• High patient and physician satisfaction
• Increase in diagnosis rate

PART 12: Impact of drivers

PART 13: Market challenges

• High cost of treatment
• Limited public awareness
• Side effects associated with treatment options
• Availability of alternative therapies

PART 14: Impact of drivers and challenges

PART 15: Market trends

• Strategic alliances and M&A
• Increased initiatives and programs
• Use of combination therapies
• Increase in R&D

PART 16: Vendor landscape

• Competitive scenario
• Market analysis 2015
• F. Hoffmann-La Roche
• Novartis
• Regeneron Pharmaceuticals
• Bayer HealthCare
• Other prominent vendors

PART 17: Appendix

• List of abbreviations

• PART 18: Explore Technavio